Squamous differentiation has been recognized as a manifestation of lineage plasticity and as a mechanism of therapy resistance to both EGFR and ALK inhibitors in lung adenocarcinomas57–60 as well as KRAS G12C inhibitors (adagrasib)61. Here, KRAS is linked to medical procedure.